Navin Fluorine revises EBITDA margin, plans ₹1,000 crore capex

1 Nov 2025 · 07:05 ISTpre-market1 source ↓written by the desknot a recommendation

for FY26: 28-30%
capital expenditure plan: ₹1,000 crore

Navin Fluorine International Limited has increased its EBITDA margin guidance for FY26 to 28-30%, up from 25%. The company also announced a ₹1,000 crore capital expenditure plan aimed at boosting production capabilities in the fluorochemicals sector. This move signals strong growth potential and enhanced market positioning for NFIL.

Not investment advice. For informational purposes only.

OI Charts is not a SEBI-registered investment adviser or research analyst. This bulletin was written by the OI Charts desk from the public sources listed here. It is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 1 Nov 2025, 07:05 IST.

Sourcesnews.google.com

NFIL
Chemicals

1 OctGanjam attracts ₹1 lakh crore investment in green energyHighGanjam is rapidly becoming a major industrial hub in Odisha, attracting over ₹1 lakh crore in investments, particularly in green energy and chemicals. The Gopalpur Industrial Park has secured ₹65,400 crore in commitments, enhancing its industrial significance in eastern India.
30 SeptGanesh Benzoplast sells logistics business for ₹1,154 croreHighGanesh Benzoplast signed an agreement to sell its logistics businesses for ₹1,154 crore to KKR-backed Cisternina Logistics. This divestment will allow the company to focus on its specialty chemicals sector, with the deal pending necessary approvals.
29 SeptAnupam Rasayan completes Bliss GVS Pharma acquisitionHighAnupam Rasayan India has acquired a 48.2% stake in Bliss GVS Pharma at ₹299 per share, funded by a ₹300 crore loan and ₹1,450 crore from investors. This strategic move enhances its portfolio in pharmaceuticals.
22 SeptIOL Chemicals plans ₹500 Cr investment for growthMediumIOL Chemicals announced a ₹500 crore investment in Ibuprofen expansion, CDMO formulations, and specialty chemicals. These projects aim to enhance operations and could drive 30% revenue growth, reflecting rising demand in the chemicals and pharmaceuticals sector.
22 SeptNeogen Chemicals raises ₹600 crore in oversubscribed QIPHighNeogen Chemicals raised ₹600 crore in its first QIP, attracting bids 6.5 times the shares offered. The company allotted 26,60,753 shares at ₹2,255 each, with participation from major institutional investors, indicating strong market confidence.
22 SeptIOL Chemicals invests ₹500 Cr for growth in pharmaceuticalsMediumIOL Chemicals announced a ₹500 crore investment in three projects to expand Ibuprofen capacity and enter CDMO formulations. These initiatives aim to enhance revenue streams and strengthen customer relationships, potentially driving 30% revenue growth.

Navin Fluorine revises EBITDA margin, plans ₹1,000 crore capex

Related